Participated · Seed · Nov 2023

MiMARK Diagnostics, a femtech spin-off from the Vall d’Hebron Research Institute, is developing an in vitro diagnostic test to improve the diagnosis of endometrial cancer using gynecological fluids as a non‑invasive biomarker source. The company’s first product is in the final prototyping stage and will move into verification and clinical validation with the new funding. MiMARK plans to accelerate clinical verification and validation and to expand R&D into additional gynecological indications, including a potential second indication for endometriosis. The company intends to strengthen collaborations with leading institutions, healthcare professionals and industry partners to advance its diagnostic platform. Financially, MiMARK closed a seed financing round totaling €4.22M that includes significant public support via the European Commission’s EIC Accelerator.

Led · Seed · Mar 2022

Aptatek BioSciences leverages DNA aptamer technology to build simple, quantitative point-of-care diagnostics for home use by patients with chronic conditions. Its lead product, PheCheck™, is an aptamer-based at-home monitor for phenylalanine levels and has received FDA breakthrough diagnostic device designation. The company announced bridge financing from strategic investor Canterbury Scientific to support ongoing clinical development and to accelerate commercialization. The funding is intended to advance clinical work and move the PheCheck platform closer to market availability for PKU patients. Canterbury Scientific is described as a leading global OEM supplier of IVD controls and remains a strategic partner in the program. Aptatek was founded as a spin-out from Columbia University and emphasizes patient-centric home monitoring solutions for chronic disease management. Aptatek BioSciences develops aptamer-based assay chemistry for point-of-care health testing in home settings, with an initial product enabling clinical-grade monitoring of phenylketonuria (PKU). The company is a Columbia University spinout and is positioned to replace slow, centralized lab testing with an easy-to-use portable device. The $4 million seed financing will fund development and clinical validation of the first product. Proceeds will also support key hires to expand the team. Aptatek is evaluating further applications in chronic kidney disease and medication management. The company emphasizes product manufacturing and global reach as part of its commercialization plans.